Moving Medicine Forward

PureTech is led by a proven and seasoned management team. Collectively, they have overseen the research and development of products supporting 20 regulatory approvals and has been involved in the C-suite of companies acquired for more than $13 billion cumulatively.

Daphne Zohar
Founder & Chief Executive Officer
Miscellaneous Information:

Daphne Zohar is the Founder and Chief Executive Officer of PureTech and a member of the Board of Directors. PureTech is a clinical stage biotechnology company discovering, developing and commercializing highly differentiated medicines for devastating diseases including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases. PureTech has a broad and deep pipeline created through the expertise of both PureTech’s experienced research and development team and its extensive network of scientists, clinicians and industry leaders. Through this network and relationships, PureTech generated the underlying programs and platforms that have resulted in a substantial pipeline comprised of one FDA-cleared product and 24 product candidates, which includes 14 in clinical trials. Zohar created PureTech, assembling a leading team to help implement her vision for a new model of biotherapeutic development which is entrepreneurial and agile, aligned with shareholders in advancing or deprioritizing programs in a capital efficient manner, and non-binary due to the breadth and depth of the pipeline. She has been a key participant in the creation of each of the programs in PureTech’s pipeline. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT's Technology Review, the Boston Globe, and Scientific American.

Share our vision, creativity & dedication - Join PureTech Health

Share our vision, creativity & dedication.

Join PureTech